Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
ConclusionsBoM impairs immunotherapy efficacy. Accurate bone staging should be included in clinical trials with immunotherapy.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Immunotherapy | Italy Health | Liver | Lung Cancer | Non-Small Cell Lung Cancer | Urology & Nephrology